Bimatoprost 0.03 %, marketed under the trade name "Latisse" was FDA approved in 2008 for treating thin eyelashes (called eyelash hypotrichosis). Latisse helps the eyebrows a bit. Dr. Jean Carruthers and colleagues set out to study whether Latisse benefits the eyebrows in those with sparse eyebrows. They performed a randomized double blind study of 357 adults with eyebrow thinnng (hyotrichosis). 118 patients received Latisse twice daily for 7 months, 118 received Latisse once daily for 7 months and 121 patients received a placebo daily. The primary end point of the investigation was eyebrow fullness after 7 months of use. In general, bimatoprost helped more than placebo and twice daily was only slightly better than once daily - but not by much. Subjects using Latisse once daily or twice daily had better improvements in brow fullness and darkness compared to placebo. 18 % of those using Latisse twice daily were "very satisfied" with their new brows compared to 17 % using once daily and 11.6 % using the placebo. In general, one should be prepared to wait at least two months in order to see results. Side effects were similar in all groups and there were no reports of skin hyperpigmentation or iris color change. Conclusion: Latisse can be safely used to try to stimualte eyebrow growth in those with thin brows. The effects on growth are modest and once daily is sufficient. Reference Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis. Carruthers J, et al. Dermatol Surg. 2016